- Cyclopharm (CYC) has completed a share placement to raise $30 million
- Roughly 11.5 million new fully paid ordinary shares offered at $2.60 per share
- Funds raised will primarily used to finance activities to accelerate Cyclopharm’s expansion into the U.S. market, pushing its Technegas product
- The company will also conducting a non-underwritten share purchase plan offer to existing eligible shareholders who have a registered address in Australia
- The placement shares expected to issued and commence trading on the ASX on February 1, 2021
- Cyclopharm shares are up 3.06 per cent, trading at $3.03
